Display options
Cite
Mulligan CM, Harper R, Harding J, et al. A retrospective audit of type 2 diabetes patients prescribed liraglutide in real-life clinical practice. Diabetes Ther. 2013;4(1):147-51doi: 10.1007/s13300-013-0025-z.
Mulligan, C. M., Harper, R., Harding, J., McIlwaine, W., Petruckevitch, A., & McLaughlin, D. M. (2013). A retrospective audit of type 2 diabetes patients prescribed liraglutide in real-life clinical practice. Diabetes therapy : research, treatment and education of diabetes and related disorders, 4(1), 147-51. https://doi.org/10.1007/s13300-013-0025-z
Mulligan, Ciara M, et al. "A retrospective audit of type 2 diabetes patients prescribed liraglutide in real-life clinical practice." Diabetes therapy : research, treatment and education of diabetes and related disorders vol. 4,1 (2013): 147-51. doi: https://doi.org/10.1007/s13300-013-0025-z
Mulligan CM, Harper R, Harding J, McIlwaine W, Petruckevitch A, McLaughlin DM. A retrospective audit of type 2 diabetes patients prescribed liraglutide in real-life clinical practice. Diabetes Ther. 2013 Jun;4(1):147-51. doi: 10.1007/s13300-013-0025-z. Epub 2013 May 29. PMID: 23715814; PMCID: PMC3687089.
Copy Download .nbib Format: NLM
Share it on

Diabetes Ther. 2013 Jun;4(1):147-51. doi: 10.1007/s13300-013-0025-z. Epub 2013 May 29.

A retrospective audit of type 2 diabetes patients prescribed liraglutide in real-life clinical practice.

Diabetes therapy : research, treatment and education of diabetes and related disorders

Ciara M Mulligan, Roy Harper, Janet Harding, Werner McIlwaine, Ann Petruckevitch, Darren M McLaughlin

Affiliations

  1. Diabetes Department, Ulster Hospital, Dundonald, Belfast, BT16 1RH, Northern Ireland, UK, [email protected].

PMID: 23715814 PMCID: PMC3687089 DOI: 10.1007/s13300-013-0025-z

Abstract

BACKGROUND: In phase 3 trials, the once-daily human glucagon-like peptide-1 analog liraglutide provided effective glycemic control with low rates of hypoglycemia, weight loss, and reduced systolic blood pressure (SBP) in patients with type 2 diabetes. Through a retrospective clinical audit, the authors aimed to assess the clinical effectiveness of liraglutide, from initiation to first hospital visit, when prescribed at a center in Northern Ireland.

METHODS: Patients attending Ulster Hospital who were prescribed liraglutide (June 2009-September 2010) and assessed both at baseline and first post-initiation visit were included in the analysis. The primary endpoint was change in glycated hemoglobin (HbA1c) from baseline. Weight, blood pressure, and frequency of hypoglycemic events were also assessed.

RESULTS: Data from 193 patients are reported (baseline HbA1c 9.0%, mean age 55.8 years, diabetes duration 8.8 years, 66.8% male). Average time to first visit after initiation was 13.5 weeks, at which point 174 patients (90.2%) were prescribed 1.2 mg liraglutide. Mean change in HbA1c from initiation to first visit was -0.9%, while mean body weight change was -2.4 kg and change in SBP was -2.0 mmHg. Transient gastrointestinal side effects were experienced by 11.9% of patients. The number of patients experiencing minor hypoglycemic events was low (5.7%) and no major events were reported.

CONCLUSION: Data from clinical studies translate into clinical practice: liraglutide provided improved glycemic control after 13.5 weeks of treatment, accompanied by weight loss and low incidence of hypoglycemia.

References

  1. Lancet. 2009 Feb 7;373(9662):473-81 - PubMed
  2. Diabetologia. 2009 Oct;52(10):2046-55 - PubMed
  3. J Med Chem. 2004 Aug 12;47(17):4128-34 - PubMed
  4. Diabet Med. 2009 Mar;26(3):268-78 - PubMed
  5. Diabetes Care. 2012 Jul;35(7):1446-54 - PubMed
  6. Lancet. 2010 Apr 24;375(9724):1447-56 - PubMed
  7. Diabetes Care. 2009 Jan;32(1):84-90 - PubMed
  8. Lancet. 2009 Jul 4;374(9683):39-47 - PubMed
  9. Postgrad Med. 2011 Jan;123(1):53-65 - PubMed
  10. Ann Intern Med. 2011 Jan 18;154(2):103-12 - PubMed
  11. Diabetes Care. 2009 Jul;32(7):1224-30 - PubMed

Publication Types